Herb-drug interaction of gastrodiae rhizoma on carbamazepine: A pharmacokinetic study in rats. 2020

Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.

Gastrodiae Rhizoma (GR), is a traditional Chinese Medicine that has been used for neurological disorders, including epilepsy. Epilepsy patients may be treated with adjunctive therapy of GR with antiepileptic drugs (AEDs). In particular, carbamazepine (CBZ) is of high potential to interact with concurrent treatment of Chinese Medicine. This study was to investigate the herb-drug interactions of GR and CBZ, an AED, through pharmacokinetic approach in rats. We adopted a high-performance liquid chromatography (HPLC) system to quantify the plasma level of CBZ and its metabolite (carbamazepine-10, 11-epoxide, CBZE). The method was validated as per instructions under United States Food and Drug Administration (USFDA) guidance. For the herb-drug interaction study, rats were randomly divided into four different treatment groups: single-dose CBZ treatment, single-dose CBZ/GR treatment, 2-week course of CBZ treatment and 2-week course of CBZ/GR treatment. Our results demonstrated the auto-induction of CBZ metabolization when comparing single-dose with 2-week course of CBZ treatment. Pharmacokinetic interactions were noted in concomitant use of GR with CBZ by comparing two single-dose treatments (CBZ versus CBZ/GR). Our data showed that GR increased the mean residence time (MRT0-t) and the time taken to reach the maximum concentration (Tmax) of CBZ in single-dose of CBZ/GR treatment. The maximum drug concentration (Cmax) of CBZ was reduced in single-dose CBZ/GR treatment. When comparing the 2-week course of CBZ treatment with the 2-week course of CBZ/GR treatment, the MRT0-t and half-life of CBZ were increased. The AUC0-t, the Cmax and the half-life of CBZE were increased. CBZ/GR treatment may reduce the auto-induction of CBZ over 2 weeks. While the reduction of auto-induction could enhance the therapeutic effects of CBZ, it could also lead to an increase in neurological side effects and non-neurological adverse effects. Our results provided preclinical evidence of herb-drug interaction, which may have implications for epilepsy patients treated with GR.

UI MeSH Term Description Entries
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D041743 Herb-Drug Interactions The adverse or beneficial effect of MEDICINAL HERBS on the activity, metabolism, or toxicity of PHARMACEUTICALS. Adverse Herb-Drug Interactions,Beneficial Herb-Drug Interactions,Drug-Herb Interactions,Drug-Plant Interactions,Herbal Drug Interactions,Plant-Drug Interactions,Adverse Herb Drug Interactions,Adverse Herb-Drug Interaction,Beneficial Herb Drug Interactions,Beneficial Herb-Drug Interaction,Drug Herb Interactions,Drug Interaction, Herbal,Drug Interactions, Herbal,Drug Plant Interactions,Drug-Herb Interaction,Drug-Plant Interaction,Herb Drug Interactions,Herb-Drug Interaction,Herb-Drug Interaction, Adverse,Herb-Drug Interaction, Beneficial,Herb-Drug Interactions, Adverse,Herb-Drug Interactions, Beneficial,Herbal Drug Interaction,Interaction, Adverse Herb-Drug,Interaction, Beneficial Herb-Drug,Interaction, Drug-Herb,Interaction, Drug-Plant,Interaction, Herb-Drug,Interaction, Herbal Drug,Interaction, Plant-Drug,Interactions, Adverse Herb-Drug,Interactions, Beneficial Herb-Drug,Interactions, Drug-Herb,Interactions, Drug-Plant,Interactions, Herb-Drug,Interactions, Herbal Drug,Interactions, Plant-Drug,Plant Drug Interactions,Plant-Drug Interaction

Related Publications

Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
April 2020, European journal of drug metabolism and pharmacokinetics,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
March 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
July 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
November 2012, Journal of ethnopharmacology,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
September 2012, Toxicology and applied pharmacology,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
January 2014, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
September 1995, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
September 2020, British journal of clinical pharmacology,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
January 2013, Evidence-based complementary and alternative medicine : eCAM,
Ka Lai Yip, and Xuelin Zhou, and Ping Chook, and Ping Chung Leung, and Steven Schachter, and Vincent C T Mok, and Thomas W H Leung, and Chi Man Koon, and Howan Leung
January 2008, Indian journal of pharmaceutical sciences,
Copied contents to your clipboard!